TNF-α inhibitors are a group of anti-inflammatory biologics that are used for the treatment of rheumatologic diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease, as well as scleritis and uveitis.[41] Five anti-TNF- α drugs are currently approved for the use in autoimmune diseases, including four monoclonal antibodies (infliximab, adalimumab, golimumab, and certolizumab) and a soluble receptor blocker (etanercept).[46] All of these medications have been paradoxically associated with the development of anterior uveitis and chorioretinitis. This evidence concerns the gene TNF and inflammatory bowel disease.